Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idenix confirms cull of two on-hold HCV programs

This article was originally published in Scrip

Executive Summary

It seemed highly likely that Idenix Pharmaceuticals would end development of IDX184 and IDX19368 - which have been on a clinical hold since August - for treatment of the hepatitis C virus (HCV) when the company said in late January that it would begin Phase II testing of the HCV drug IDX719 in combination with two Janssen Pharmaceuticals drugs. Late in the afternoon of 4 February Idenix confirmed the market's suspicions.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020287

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel